Engineered AAV Capsids for Cross-Species CNS and Kidney Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing AAV-based gene therapies face challenges such as immune responses, difficulty in targeting specific tissues, particularly in the CNS and PNS, and variability in transduction efficiency across different species, leading to manufacturing burdens and reduced efficacy.
Innovation Solution
Development of recombinant AAV vectors with modified capsid proteins that include specific amino acid substitutions to enhance transduction efficiency, evade host antibodies, and improve tissue tropism, allowing for cross-species compatibility and targeted delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high doses of AAV-based therapies are administered to achieve sufficient transduction of target CNS and PNS tissues, then transduction efficiency is improved, but the risk of side effects and undesired immune responses increases
Solution Approach 1:
The patent applies local quality by engineering capsid proteins with specific amino acid substitutions at particular positions (e.g., positions 452-458 and 586-592) to create targeted modifications. These localized changes in capsid structure enable selective enhancement of CNS and PNS tissue transduction while maintaining safety profiles, allowing effective delivery without requiring high doses that would cause systemic side effects.
Solution Approach 2:
The patent employs parameter changes by systematically varying amino acid sequences in the capsid protein to optimize transduction properties. By modifying specific parameters of the capsid structure through amino acid substitutions, the invention achieves enhanced transduction efficiency in target tissues while reducing the vector dose required, thereby minimizing immune responses and side effects.
2Ease of manufacture
If known AAV serotypes are used with their specific tissue tropism, then manufacturing is simplified, but the ability to target specific tissues such as kidney is limited
Solution Approach 1:
The patent applies universality by creating capsid protein variants that can target multiple tissue types including CNS, PNS, and kidney tissues. The engineered capsids maintain compatibility with standard AAV manufacturing processes while gaining enhanced versatility to target previously difficult-to-access tissues, making the vector platform universally applicable across multiple indications and tissue types.
Solution Approach 2:
The patent uses local quality by introducing specific amino acid substitutions at defined positions in the capsid protein sequence to confer kidney tissue targeting capability. These localized modifications preserve the overall capsid structure and manufacturing characteristics of known AAV serotypes while adding the new functionality to target kidney and other previously inaccessible tissues.
3Ease of operation
If AAV-based therapies are administered systemically to treat CNS disorders, then non-invasive delivery is achieved, but the blood brain barrier impedes access to CNS tissues
Solution Approach 1:
The patent applies parameter changes by modifying capsid protein amino acid sequences to alter the physical and biological properties of the AAV vector. These changes enable the vector to traverse the blood-brain barrier through systematic variation of capsid surface properties, allowing systemic administration to successfully deliver therapeutic cargo to CNS tissues without requiring invasive procedures.
Solution Approach 2:
The engineered capsid protein acts as an intermediary that facilitates interaction between the AAV vector and the blood-brain barrier. The modified capsid structure mediates crossing of this biological barrier, enabling systemic delivery to reach CNS target tissues by serving as a bridge between the circulating vector and the protected brain and spinal cord tissues.
4Measurement precision
If AAV transduction is tested in various model organisms during clinical development, then species-specific variability is observed, but accurate prediction of human response is difficult
Solution Approach 1:
The patent applies universality by engineering capsid proteins with cross-species compatibility that enables consistent transduction performance across multiple species including mice, non-human primates, and humans. The modified capsids maintain their targeting and transduction properties across species boundaries, allowing data from animal models to more reliably predict human clinical outcomes and reducing species-specific variability.
Data Source
AI summary
The present disclosure provides adeno-associated virus (AAV) vectors, comprising coevolved capsid variant proteins, pharmaceutical compositions, methods of making, and methods for delivering such to a subject.